The key idea here is data integrity: records must be complete, accurate, and fully explainable so the study’s results can be trusted. When investigators review data submitted to the FDA, they look for anything that calls that trust into question. Inconsistent and/or unexplained entries signal that the data aren’t being recorded and reported transparently. They create doubt about whether observations were recorded correctly, whether edits were authorized, or whether data were fabricated or inappropriately altered. That kind of flag prompts investigators to dig deeper into the entire data set and the study conduct. Other issues like missing pages, outdated test methods, or unapproved methods are also problematic and can lead to noncompliance, but they don’t point to a data integrity problem as directly or as early as inconsistent or unexplained data entries. The consistency and justification of what was recorded is the first line of evidence that something in the data handling may be compromised.

In this context, the environment of an animal housing room is defined by the actual physical conditions the animals experience, with temperature and relative humidity being the most fundamental measures of those conditions. These two factors directly influence comfort, metabolism, hydration, and health, and they’re routinely monitored to keep animals within a stable, acceptable range. While lighting duration, noise level, and ventilation rate matter for welfare and air quality, they describe additional aspects of the environment rather than defining its core state. Keeping temperature and humidity within appropriate ranges ensures animals remain comfortable and that experimental results are reliable, which is why this option best captures the environment.

Cross-border recognition of GLP data is what this item is testing. An MOU between an OECD-member country and the U.S. is meant to foster mutual acceptance of GLP-compliant studies, so that final reports and data generated in either country under each nation’s GLP regulations can be used in regulatory submissions in the other country. This arrangement helps avoid duplicative testing and speeds up the regulatory process while preserving data quality and traceability—data produced in one country under its GLP rules is acceptable to the other country as long as it meets those GLP requirements. The other options imply restricting acceptance to data from only one side or forbidding cross-acceptance, which is not the intended outcome of such an MOU.

Data integrity in GLP means data are accurate, complete, and verifiable, so they can be reviewed and audited. In practice, this means records are attributable to the person who generated them, legible, contemporaneous with the observation, original or a true copy, and accurate. The systems used to collect and store data should preserve their authenticity over time, with proper change control and traceability so an auditor can confirm what happened and when. The idea that data may be approximate if the study design is robust misses the core point: integrity requires data truly reflect what was observed, not a best-guess version. Robust design does not excuse inaccuracy or incompleteness. Likewise, it’s not acceptable to limit the expectation of integrity to final report data; regulators and QA expect raw data and source documents to be complete and trustworthy, because the final conclusions depend on the entire data trail. Finally, data integrity isn’t optional because QA is strong—QA supports integrity, but it cannot substitute for proper data capture, retention, and traceability across the study.

The key idea here is mutual recognition of GLP data between the United States and an OECD member country. When a GLP memorandum of understanding exists, final reports and data produced in either country under that country’s GLP regulations are acceptable in the other country’s regulatory system. In practice, this means a study conducted in one jurisdiction can be used to support regulatory decisions in the other, as long as it was performed under the relevant GLP rules and is properly documented. So data from the U.S. can be accepted in the OECD member country and data from that country can be accepted in the U.S., without needing to redo the study under the other country’s GLP framework.